Status:
COMPLETED
Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan
Lead Sponsor:
Pfizer
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
20-70 years
Phase:
PHASE2
Brief Summary
To evaluate the dose-response relationship of 5 dose of CP-690,550, compared to placebo for the treatment of signs and symptoms in patients with active RA who failed an adequate trial of therapy with ...
Eligibility Criteria
Inclusion
- Subjects must have failed an adequate trial of therapy with at least 1 DMARD due to lack of efficacy or toxicity.
Exclusion
- Current therapy with any DMARD
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
318 Patients enrolled
Trial Details
Trial ID
NCT00687193
Start Date
March 1 2009
End Date
July 1 2010
Last Update
March 25 2013
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Nagoya, Aichi-ken, Japan
2
Pfizer Investigational Site
Chiba, Chiba, Japan
3
Pfizer Investigational Site
Narashino, Chiba, Japan
4
Pfizer Investigational Site
Yotukaidou, Chiba, Japan